Exelixis (EXEL) News Today $36.85 +1.76 (+5.02%) Closing price 04:00 PM EasternExtended Trading$36.85 0.00 (0.00%) As of 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Why Exelixis Stock Trounced the Market on ThursdayFebruary 21 at 6:31 PM | fool.comWhy Is Cancer-Focused Exelixis Stock Trading Higher On Friday?February 21 at 1:30 PM | benzinga.comExelixis' (NASDAQ:EXEL) Earnings May Just Be The Starting PointFebruary 21 at 11:42 AM | finance.yahoo.comHussman Strategic Advisors Inc. Has $2.10 Million Stock Position in Exelixis, Inc. (NASDAQ:EXEL)Hussman Strategic Advisors Inc. lessened its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 50.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 63,000 shares of the biotechnology company's stock afterFebruary 21 at 6:37 AM | marketbeat.comIeq Capital LLC Purchases New Shares in Exelixis, Inc. (NASDAQ:EXEL)Ieq Capital LLC acquired a new position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 194,181 shares of the biotechnology company's stock, valued at approximately $6,46February 21 at 4:45 AM | marketbeat.comInsider Selling: Exelixis, Inc. (NASDAQ:EXEL) Director Sells 12,210 Shares of StockExelixis, Inc. (NASDAQ:EXEL - Get Free Report) Director Mary C. Beckerle sold 12,210 shares of Exelixis stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $34.88, for a total value of $425,884.80. Following the transaction, the director now directly owns 30,406 shares in the company, valued at approximately $1,060,561.28. The trade was a 28.65 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.February 20 at 11:18 PM | marketbeat.comExelixis Announces a Newly Authorized $500 Million Stock Repurchase ProgramFebruary 20 at 5:05 PM | businesswire.comMary C. Beckerle Sells 12,210 Shares of Exelixis, Inc. (NASDAQ:EXEL) StockFebruary 20 at 5:10 AM | insidertrades.comConvergence Investment Partners LLC Takes Position in Exelixis, Inc. (NASDAQ:EXEL)Convergence Investment Partners LLC acquired a new stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 23,488 shares of the biotechnology company's stock, valued aFebruary 20 at 4:45 AM | marketbeat.comState of New Jersey Common Pension Fund D Has $3.31 Million Stake in Exelixis, Inc. (NASDAQ:EXEL)State of New Jersey Common Pension Fund D lessened its stake in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 7.5% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 99,467 shares of the biotechnology company's stockFebruary 20 at 3:54 AM | marketbeat.comStockNews.com Upgrades Exelixis (NASDAQ:EXEL) to "Strong-Buy"February 20 at 3:01 AM | americanbankingnews.comExelixis (NASDAQ:EXEL) Raised to Strong-Buy at StockNews.comStockNews.com upgraded shares of Exelixis from a "buy" rating to a "strong-buy" rating in a research note on Wednesday.February 19 at 2:18 AM | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Sees Large Decrease in Short InterestExelixis, Inc. (NASDAQ:EXEL - Get Free Report) saw a significant decline in short interest in the month of January. As of January 31st, there was short interest totalling 13,090,000 shares, a decline of 9.5% from the January 15th total of 14,460,000 shares. Currently, 4.7% of the company's shares are short sold. Based on an average daily volume of 2,200,000 shares, the short-interest ratio is presently 6.0 days.February 18 at 5:34 PM | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Shares Sold by New York State Teachers Retirement SystemNew York State Teachers Retirement System cut its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 6.2% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 411,812 shares of the biotechnology company's stock after selling 27,410 shares during the periodFebruary 18 at 3:44 AM | marketbeat.comExelixis announces final five-year follow-up results from CheckMate -9ERFebruary 17, 2025 | markets.businessinsider.comFive-year results see Exelixis’ RCC therapy extending overall survivalFebruary 17, 2025 | finance.yahoo.comNew Mexico Educational Retirement Board Sells 8,345 Shares of Exelixis, Inc. (NASDAQ:EXEL)New Mexico Educational Retirement Board trimmed its position in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 12.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 57,855 shares ofFebruary 17, 2025 | marketbeat.comVan ECK Associates Corp Buys 78,740 Shares of Exelixis, Inc. (NASDAQ:EXEL)Van ECK Associates Corp lifted its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 45.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 252,324 shares of the biotechnology company's stock after purchasing an additFebruary 17, 2025 | marketbeat.comExelixis Full Year 2024 Earnings: EPS Beats ExpectationsFebruary 16, 2025 | finance.yahoo.comEquities Analysts Set Expectations for Exelixis Q3 EarningsFebruary 16, 2025 | americanbankingnews.comExelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX ® (cabozantinib) in Combination with Opdivo ® (nivolumab) in Patients with Advanced Kidney Cancer atFebruary 15, 2025 | investing.comExelixis Announces Final Five-Year Follow-up Results from CheckMate -9ER Trial Evaluating CABOMETYX® (cabozantinib) in Combination with Opdivo® (nivolumab) in Patients with Advanced Kidney Cancer at ASCO GU 2025February 15, 2025 | businesswire.comEquities Analysts Offer Predictions for Exelixis Q3 EarningsExelixis, Inc. (NASDAQ:EXEL - Free Report) - Investment analysts at Leerink Partnrs upped their Q3 2025 earnings per share estimates for shares of Exelixis in a research report issued on Tuesday, February 11th. Leerink Partnrs analyst A. Berens now forecasts that the biotechnology company will poFebruary 15, 2025 | marketbeat.comWilliam Blair Has Bullish Estimate for Exelixis Q1 EarningsExelixis, Inc. (NASDAQ:EXEL - Free Report) - Research analysts at William Blair raised their Q1 2025 earnings estimates for shares of Exelixis in a research report issued on Tuesday, February 11th. William Blair analyst A. Hsieh now anticipates that the biotechnology company will post earnings ofFebruary 15, 2025 | marketbeat.comExelixis to Participate in the Citi 2025 Virtual Oncology Leadership SummitFebruary 15, 2025 | finance.yahoo.comWilliam Blair Predicts Exelixis' Q1 Earnings (NASDAQ:EXEL)February 15, 2025 | americanbankingnews.comExelixis, Inc. (NASDAQ:EXEL) Holdings Lifted by Allspring Global Investments Holdings LLCAllspring Global Investments Holdings LLC boosted its position in shares of Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 82.1% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,562,790 shares of the biotecFebruary 14, 2025 | marketbeat.comExelixis, Inc. (NASDAQ:EXEL) Shares Sold by State of Alaska Department of RevenueState of Alaska Department of Revenue lowered its stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 74.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 32,561 shares of the biotechnology company's sFebruary 14, 2025 | marketbeat.comExelixis (NASDAQ:EXEL) Shares Up 6.7% After Analyst UpgradeFebruary 14, 2025 | americanbankingnews.comExelixis, Inc. (NASDAQ:EXEL) Q4 2024 Earnings Call TranscriptFebruary 13, 2025 | msn.comBarclays Issues Positive Forecast for Exelixis (NASDAQ:EXEL) Stock PriceBarclays raised their target price on shares of Exelixis from $25.00 to $29.00 and gave the stock an "equal weight" rating in a research report on Thursday.February 13, 2025 | marketbeat.comHC Wainwright Reiterates Buy Rating for Exelixis (NASDAQ:EXEL)HC Wainwright restated a "buy" rating and issued a $40.00 target price on shares of Exelixis in a report on Thursday.February 13, 2025 | marketbeat.comExelixis price target raised to $36 from $30 at StifelFebruary 13, 2025 | markets.businessinsider.comExelixis Inc (EXEL) Q4 2024 Earnings: EPS of $0.48 Beats Estimate, Revenue Hits $567 MillionFebruary 13, 2025 | gurufocus.comSapient Capital LLC Invests $256,000 in Exelixis, Inc. (NASDAQ:EXEL)Sapient Capital LLC purchased a new stake in Exelixis, Inc. (NASDAQ:EXEL - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 7,700 shares of the biotechnology company's stock, valued at aFebruary 13, 2025 | marketbeat.comExelixis price target raised to $45 from $38 at CitiFebruary 13, 2025 | markets.businessinsider.comExelixis Hold Rating Maintained Amidst Stable Financials and Awaited Trial DataFebruary 13, 2025 | tipranks.comStifel raises Exelixis stock price target to $36, maintains holdFebruary 12, 2025 | msn.comExelixis price target raised to $29 from $25 at BarclaysFebruary 12, 2025 | markets.businessinsider.comExelixis price target raised to $38 from $34 at TD CowenFebruary 12, 2025 | markets.businessinsider.comExelixis (NASDAQ:EXEL) Stock Price Expected to Rise, Citigroup Analyst SaysCitigroup increased their price objective on Exelixis from $38.00 to $45.00 and gave the stock a "buy" rating in a report on Wednesday.February 12, 2025 | marketbeat.comExelixis (NASDAQ:EXEL) Price Target Raised to $36.00 at Stifel NicolausStifel Nicolaus upped their price objective on Exelixis from $30.00 to $36.00 and gave the company a "hold" rating in a research note on Wednesday.February 12, 2025 | marketbeat.comExelixis' (EXEL) "Equal Weight" Rating Reiterated at StephensStephens reiterated an "equal weight" rating and set a $29.00 price objective on shares of Exelixis in a research note on Wednesday.February 12, 2025 | marketbeat.comExelixis' (EXEL) "Buy" Rating Reiterated at GuggenheimGuggenheim reiterated a "buy" rating and issued a $42.00 price target on shares of Exelixis in a report on Wednesday.February 12, 2025 | marketbeat.comExelixis (NASDAQ:EXEL) Stock Price Up 6.7% on Analyst UpgradeExelixis (NASDAQ:EXEL) Stock Price Up 6.7% After Analyst UpgradeFebruary 12, 2025 | marketbeat.comExelixis (NASDAQ:EXEL) Given New $38.00 Price Target at Piper SandlerPiper Sandler raised their target price on Exelixis from $37.00 to $38.00 and gave the company an "overweight" rating in a report on Wednesday.February 12, 2025 | marketbeat.comExelixis: Cabozantinib Continues To Grow, Zanzalintinib Could Soon FollowFebruary 12, 2025 | seekingalpha.comHold Rating on Exelixis Amid Uncertainty in Key Pipeline Asset and Market OpportunitiesFebruary 12, 2025 | tipranks.comExelixis’s Growth Potential Bolstered by Cabozantinib Expansion and Promising New Drug DevelopmentsFebruary 12, 2025 | tipranks.comExelixis stock holds firm with $41 target from JMP SecuritiesFebruary 12, 2025 | msn.com Get Exelixis News Delivered to You Automatically Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. Email Address EXEL Media Mentions By Week EXEL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. EXEL News Sentiment▼0.690.60▲Average Medical News Sentiment EXEL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. EXEL Articles This Week▼3111▲EXEL Articles Average Week Get Exelixis News Delivered to You Automatically Sign up to receive the latest news and ratings for EXEL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Alnylam Pharmaceuticals News Biogen News United Therapeutics News Incyte News BioMarin Pharmaceutical News Neurocrine Biosciences News Exact Sciences News Repligen News Halozyme Therapeutics News Madrigal Pharmaceuticals News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:EXEL) was last updated on 2/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon “obliterates” Bill Gates?All 10 of the world's biggest money managers follow my work, and the Pentagon, the FBI and Harvard professors ...Altimetry | SponsoredNVDA Crash UpdateAn overseas AI rival sent shockwaves through the U.S. tech market last week... Leaving millions of investor...Chaikin Analytics | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Is Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again ...Paradigm Press | Sponsored My 2025 AI BlueprintI first recommended Bitcoin at $300 in 2013 … before it went up 33,645%. Now, I am revealing my 2025 AI Blu...Weiss Ratings | SponsoredBetter than Bitcoin – and potentially more profitableThe world is obsessed with Bitcoin again... And for a good reason: It just soared beyond $100,000. Bitcoin ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exelixis, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exelixis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
